Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry

Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial

(2018) Kejal Kantarci et al.   NEUROLOGY

Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis

(2017) Noriko Itoh et al.   JOURNAL OF NEUROIMMUNOLOGY

Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes

(2017) Noriko Itoh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury

(2017) E.B. Engler-Chiurazzi et al.   PROGRESS IN NEUROBIOLOGY

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial

(2016) Rhonda R Voskuhl et al.   LANCET NEUROLOGY

Grey matter atrophy is associated with disability increase in natalizumab-treated patients

(2016) Ethel Ciampi et al.   Multiple Sclerosis Journal

Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis

(2016) Allan MacKenzie-Graham et al.   JAMA Neurology

Grey matter atrophy is associated with disability increase in natalizumab-treated patients

(2016) Ethel Ciampi et al.   Multiple Sclerosis Journal

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

(2016) Pierre Branger et al.   PLoS One

Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI

(2015) Jie Wen et al.   NeuroImage-Clinical

Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings

(2015) Flavia Mattioli et al.   PLoS One

Neuroprotective effects of testosterone treatment in men with multiple sclerosis

(2014) Florian Kurth et al.   NeuroImage-Clinical

The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis

(2012) A. Ceccarelli et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

The Attention System of the Human Brain: 20 Years After

(2012) Steven E. Petersen et al.   Annual Review of Neuroscience

Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis

(2012) Allan J. MacKenzie-Graham et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease

(2012) Marina O Ziehn et al.   LABORATORY INVESTIGATION

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis

(2012) F Rinaldi et al.   Multiple Sclerosis Journal

Sex-related factors in multiple sclerosis susceptibility and progression

(2012) Rhonda R. Voskuhl et al.   Nature Reviews Neurology

Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration

(2011) Rory D. Spence et al.   FRONTIERS IN NEUROENDOCRINOLOGY

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

(2011) M Calabrese et al.   Multiple Sclerosis Journal

MRI predictors of cognitive outcome in early multiple sclerosis

(2011) M. S. A. Deloire et al.   NEUROLOGY

Neuroprotection mediated through estrogen receptor-  in astrocytes

(2011) R. D. Spence et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oestrogen receptor β ligand: a novel treatment to enhance endogenous functional remyelination

(2010) Daniel K. Crawford et al.   BRAIN

Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis—A longitudinal MRI study

(2010) Kerstin Bendfeldt et al.   BRAIN RESEARCH

Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes

(2010) Declan T. Chard et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis

(2010) I. J. van den Elskamp et al.   NEURORADIOLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gray- and White-Matter Changes 1 Year after First Clinical Episode of Multiple Sclerosis: MR Imaging

(2010) Eytan Raz et al.   RADIOLOGY

Neuroprotective effects of estrogens following ischemic stroke

(2009) Shotaro Suzuki et al.   FRONTIERS IN NEUROENDOCRINOLOGY

Adaptive non-local means denoising of MR images with spatially varying noise levels

(2009) José V. Manjón et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Why Sex Matters: Brain Size Independent Differences in Gray Matter Distributions between Men and Women

(2009) E. Luders et al.   JOURNAL OF NEUROSCIENCE

Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis

(2009) Marco Battaglini et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERα)

(2009) Stefan M Gold et al.   LABORATORY INVESTIGATION

Gray matter atrophy in multiple sclerosis: A longitudinal study

(2008) Elizabeth Fisher et al.   ANNALS OF NEUROLOGY

Sex differences in a transgenic rat model of Huntington's disease: decreased 17β-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males

(2008) Felix J. Bode et al.   HUMAN MOLECULAR GENETICS

Cognitive impairment in multiple sclerosis

(2008) Nancy D Chiaravalloti et al.   LANCET NEUROLOGY

Estrogen and SERM neuroprotection in animal models of Parkinson's disease

(2008) Marc Morissette et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes

(2008) Antonia Ceccarelli et al.   NEUROIMAGE

Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis — A longitudinal voxel-based morphometry study

(2008) Kerstin Bendfeldt et al.   NEUROIMAGE

The multiple dimensions of sustained attention

(2007) Tim Shallice et al.   CORTEX